Boehringer Ingelheim expands animal health portfolio in India with the launch of NexGard® (afoxolaner) Small and Medium

India, 8^th August 2023 – Boehringer Ingelheim, a global leader in human and animal health, today announced the launch of NexGard® (afoxolaner) S and M in India. This expansion of the NexGard® product line for small (weighing 2-4 kgs) and medium (weighing 4-10kgs) dogs comes after the successful introduction of NexGard® X and L earlier in 2020.

NexGard® is indicated for use in dogs and puppies from eight weeks of age and is delivered as a monthly treatment in highly palatable flavored chewables that kill fleas before they can lay eggs, ticks and mites. NexGard® small and medium is suitable for puppies as young as eight weeks old, even with a body weight of two kgs. It is easy-to-administer, and a convenient and effective way to keep pets safe from harmful parasites. Moreover, NexGard® (afoxolaner) is the only product that is FDA-approved to prevent Lyme infections in dogs as a result of killing black-legged ticks.

"The tropical conditions in India provides an ideal weather for the survival and propagation of flea-borne and tick-borne pathogens in dogs. These can also be easily transmitted from animal to humans, leading to a larger health concerns. It is thus crucial for pet parents to be aware of and administer regular parasite control for their pets. With the introduction of NexGard® S and M, Boehringer Ingelheim aims to ensure the same high-quality protection for small and medium-sized dogs, as their larger counterparts. It reflects our unwavering commitment towards helping Indian veterinarians and pet owners in safeguarding their pets’ health and well-being," said Dr. Vinod Gopal, Director - Country Head, Animal Health, Boehringer Ingelheim India.

Pet parenting in India has grown multifold over the last few years, and is growing at a 12% CAGR each year. India today has over 32 million pets, which is a 61%ⁱ spike as compared to 2018 numbers.ⁱⁱ This puts an increased focus on pet health and care among modern pet parents.

Flea and tick infestation is a perennial problem in dogs and thrives especially in humid and warm conditions, which can cause itching, skin irritation, and infections like flea allergic dermatitis, anemia, and tapeworm. It can also transmit various diseases caused by bacteria and viruses like erlichiosis, lyme disease, tick paralysis, etc.; which can also be transmitted to humans. Pet parasitic treatment not only reduces the use of antibiotics to prevent infections, but also protects the health of the pets, making pet and human co-living safe and meaningful.

About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since Boehringer Ingelheim takes a long-term perspective. Around 53,000 employees serve more than 130 markets in three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Learn more at www.boehringer-ingelheim.com

Established in 2003, Boehringer Ingelheim India manages India and the neighboring markets’ operations of the global enterprise. The Company enables access to innovative products as part of its Human Pharma and Animal Health businesses. The focus Human Pharma therapy areas include diabetes, cardiovascular and respiratory conditions. Learn more at www.boehringer-ingelheim.in